Description

Octreotid-MB Solution for Injections 0.1 mg/m 1ml. Vials №5

Ingredients:

Octreotide acetate is the active ingredient in Octreotid-MB solution for injections 0.1 mg/m 1ml. Vials №5. It belongs to a class of medications called somatostatin analogs.

Dosage:

The recommended dosage of Octreotid-MB solution for injections is determined by the healthcare provider based on the individual’s condition. It is usually administered as a subcutaneous injection.

Indications:

Octreotid-MB solution is indicated for the treatment of acromegaly, carcinoid tumors, and vasoactive intestinal peptide-secreting tumors.

Contraindications:

Contraindications include hypersensitivity to octreotide or any of the ingredients in the formulation.

Directions:

It is important to follow the directions provided by the healthcare provider for the correct administration of Octreotid-MB solution for injections.

Scientific Evidence:

Studies have shown that Octreotid-MB solution is effective in reducing growth hormone levels in patients with acromegaly. Research published in the Journal of Clinical Endocrinology & Metabolism demonstrated the efficacy of octreotide in controlling symptoms and tumor growth in patients with neuroendocrine tumors.

Additional Information:

Octreotid-MB solution for injections may cause side effects such as diarrhea, abdominal pain, and gallstones. It is important to discuss any concerns or potential interactions with other medications with a healthcare provider before starting treatment.

Pharmacological Effects: Octreotide acts by binding to somatostatin receptors, inhibiting the release of growth hormone, insulin, glucagon, and other hormones. This results in the suppression of excessive hormone secretion seen in conditions like acromegaly and carcinoid tumors.

Clinical Trials: Clinical trials have shown that Octreotid-MB solution is well-tolerated and effective in managing symptoms associated with neuroendocrine tumors. A study published in the European Journal of Cancer evaluated the long-term efficacy and safety of octreotide in patients with carcinoid tumors, demonstrating its role in symptom control and tumor stabilization.